Travere Therapeutics (TVTX) Capital Expenditures (2013 - 2025)

Travere Therapeutics has reported Capital Expenditures for 13 years, with the latest figure at $140000.0 in Q3 2025.

• For the quarter ending Q3 2025, Capital Expenditures changed N/A year-over-year to $140000.0; the trailing twelve-month figure through Sep 2025 stood at $222000.0 (up 107.48% YoY), and the FY2023 full-year result was $668000.0, up 249.74% from the prior year.
• Capital Expenditures for Q3 2025 stood at $140000.0, up from $82000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $4.5 million in Q1 2021, with the low at $3000.0 in Q2 2023.
• Historically, Capital Expenditures has averaged $441571.4 across 5 years, with a median of $92500.0 in 2021.
• Annual changes were most pronounced in 2022 — Capital Expenditures plunged 97.09% — and 2024, when it soared 2633.33%.
• Travere Therapeutics' Capital Expenditures stood at $154000.0 in 2021, then sank by 80.52% to $30000.0 in 2022, then fell by 16.67% to $25000.0 in 2023, then surged by 228.0% to $82000.0 in 2024, then soared by 70.73% to $140000.0 in 2025.
• The last three Capital Expenditures figures came in at $140000.0 (Q3 2025), $82000.0 (Q2 2024), and $25000.0 (Q4 2023), per Business Quant data.